Compare ABSI & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABSI | ADNT |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2016 |
| Metric | ABSI | ADNT |
|---|---|---|
| Price | $8.40 | $15.17 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 12 |
| Target Price | $15.09 | ★ $25.09 |
| AVG Volume (30 Days) | ★ 4.2M | 1.2M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.64 | ★ 93.51 |
| EPS | N/A | ★ N/A |
| Revenue | $4,534,000.00 | ★ $17,439,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.25 | $2.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.56 |
| 52 Week Low | $2.24 | $14.93 |
| 52 Week High | $12.54 | $27.32 |
| Indicator | ABSI | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 43.96 | 32.68 |
| Support Level | $7.79 | N/A |
| Resistance Level | $11.94 | $18.36 |
| Average True Range (ATR) | 1.03 | 0.86 |
| MACD | -0.30 | -0.14 |
| Stochastic Oscillator | 24.61 | 11.53 |
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Adient began trading in October 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market, including unconsolidated joint-venture business. Its share in China is around 20%, down from about 45% following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025, and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. In fiscal 2026 (ended September), consolidated revenue, excluding joint-venture sales, was $15.2 billion.